 -- In Phase 2 study, enobosarm, an oral selective androgen receptor AR agonist, had the most significant antitumor effects in heavily pretreated ARER metastatic breast cancer subjects with 40 AR expression in cancer tissue -- -- Companion diagnostic test to measure AR may be used to select ARERHER2- metastatic breast cancer subjects most likely to benefit from enobosarm treatment-- 